New Brunswick Scientific, Pall partner to develop new disposable bioreactor systems

New Brunswick Scientific, an Eppendorf Company (Edison, NJ, www.nbsc.com), and Pall Corporation (Port Washington, NY, www.pall.com) today announced a joint product development and marketing agreement to create and supply new disposable bioreactor systems.

“We are delighted to be able to partner with New Brunswick to extend our Allegro single-use technology to cover the entire range of upstream bioprocessing applications. We believe these new bioreactor systems will provide our customers with greater benefits in operational simplicity, product quality assurance, and process economics.”

The joint effort will build on the capabilities of Pall's Allegro™ single-use biocontainer platform and New Brunswick's CelliGen® bioprocess controller, to better serve upstream applications ranging from the process development laboratory to the full-scale cGMP production suite.

This partnership combines the historic market strengths of the two companies in upstream biopharmaceutical processing, strengths that have been recently augmented by New Brunswick Scientific's development of the CelliGen BLU Single-Use Stirred-Tank Bioreactor, and Pall's acquisition of MicroReactor Technologies and the Micro-24 microbioreactor.

According to Mike Sattan, New Brunswick's Vice President Marketing, "This is an exciting step forward, as the new system will enable us to offer an even broader range of bioreactor technology options, while we continue to provide a control system with the reliability, ease of use and configurability that our customers have come to expect."

Ken Frank, President Pall Life Sciences Biopharmaceuticals, said, "We are delighted to be able to partner with New Brunswick to extend our Allegro single-use technology to cover the entire range of upstream bioprocessing applications. We believe these new bioreactor systems will provide our customers with greater benefits in operational simplicity, product quality assurance, and process economics."

Source:

 New Brunswick Scientific and Pall Corporation

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Pall Corporation. (2019, June 20). New Brunswick Scientific, Pall partner to develop new disposable bioreactor systems. News-Medical. Retrieved on November 22, 2024 from https://www.news-medical.net/news/20100614/New-Brunswick-Scientific-Pall-partner-to-develop-new-disposable-bioreactor-systems.aspx.

  • MLA

    Pall Corporation. "New Brunswick Scientific, Pall partner to develop new disposable bioreactor systems". News-Medical. 22 November 2024. <https://www.news-medical.net/news/20100614/New-Brunswick-Scientific-Pall-partner-to-develop-new-disposable-bioreactor-systems.aspx>.

  • Chicago

    Pall Corporation. "New Brunswick Scientific, Pall partner to develop new disposable bioreactor systems". News-Medical. https://www.news-medical.net/news/20100614/New-Brunswick-Scientific-Pall-partner-to-develop-new-disposable-bioreactor-systems.aspx. (accessed November 22, 2024).

  • Harvard

    Pall Corporation. 2019. New Brunswick Scientific, Pall partner to develop new disposable bioreactor systems. News-Medical, viewed 22 November 2024, https://www.news-medical.net/news/20100614/New-Brunswick-Scientific-Pall-partner-to-develop-new-disposable-bioreactor-systems.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Pall enters new $500 million 5-year revolving credit facility